Topical STD/vaginal contraceptive drug studies described in FDA "Points to Consider".
This article was originally published in The Tan Sheet
TOPICAL STD/VAGINAL CONTRACEPTIVE DRUGS POINTS TO CONSIDER document recommends one-year toxicity studies in non-rodent species to support Phase II/III trials. In addition, six-month rodent studies are suggested for the drugs, which are considered for regulatory purposes to be chronically administered. The full title of FDA's recently-issued document is "Points to Consider in the Nonclinical Pharmacology/Toxicology Development of Topical Drugs Intended to Prevent the Transmission of Sexually Transmitted Diseases and/or for the Development of Drugs Intended to Act as Vaginal Contraceptives."
You may also be interested in...
Perrigo promotes in pricing, planning
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Combe sells most of its OTC brands